anti-B7-H3 antibody-based TCEs (Helixon)

靶向B7-H3/CD3 TCEs (华深智药)

Report date: 2026/05/15 20:01:45

Base Information

Drug Nameanti-B7-H3 antibody-based TCEs (Helixon)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionAnti-CD276Anti-CD3CD3 T-cell engagers
TargetsCD276 antigenT cell surface glycoprotein CD3
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesHelixon Ltd
China Registration ClassN/A

Develop Information

Active CompaniesHelixon Ltd
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A